AstraZeneca (LON:AZN) Earns “Hold” Rating from Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “hold” rating reissued by Deutsche Bank Aktiengesellschaft in a report released on Tuesday, Digital Look reports. They currently have a £117 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target points to a potential downside of 1.43% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. Citigroup raised their price target on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Jefferies Financial Group reissued a “buy” rating and issued a £175 price objective on shares of AstraZeneca in a report on Wednesday, September 9th. Berenberg Bank decreased their target price on shares of AstraZeneca from £160 to £150 and set a “buy” rating on the stock in a research report on Tuesday, September 15th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a £145 target price on shares of AstraZeneca in a research report on Tuesday, September 8th. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of £150.

AstraZeneca Stock Down 1.3%

AZN opened at £118.70 on Tuesday. AstraZeneca has a fifty-two week low of £114.04 and a fifty-two week high of £157.32. The company has a debt-to-equity ratio of 64.10, a quick ratio of 0.59 and a current ratio of 0.89. The company has a market capitalization of £184.09 billion, a P/E ratio of 17.77, a P/E/G ratio of 0.86 and a beta of 0.20. The stock has a fifty day moving average of £121.34 and a 200-day moving average of £132.75.

Insider Activity at AstraZeneca

In related news, insider Michel Demare purchased 2,500 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were bought at an average price of £121.21 per share, for a total transaction of £303,025. Insiders own 0.15% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.